Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Triple GLP-1 / GIP / Glucagon Receptor Agonist (CAS 2381089-83-2) Compound Name: Research Peptide (CAS 2381089-83-2) Classification: Research Peptide Multi-Receptor Agonist Description: This compound is a synthetic research peptide that functions as a triple agonist of the glucagon receptor (GCGR), glucose dependent insulinotropic polypeptide receptor (GIPR), and glucagon like peptide-1 receptor (GLP-1R)
Alliinase catalyzes the formation of sulfenic acids from L-cysteine sulfoxides ( Figure 2 )
Ethics declarations Ethics approval and consent to participate The study protocol was approved by the Ethics Committee of Shiraz University of Medical Sciences
& Zhou, R
Our medical team ensures your comfort throughout the process
ESSENCE Phase 3 semaglutide in MASH data supported FDA approval in March 2024 , creating a premium pricing tier in a disease category with USD 17.4 billion addressable market and no prior approved pharmacotherapy
US$ 25.06
US$ 25.56
US$ 22.11
US$ 26.72
US$ 28.07
US$ 25.24
US$ 22.80
